source
- BMS beats Q2 forecasts and lifts 2026 outlook despite delays in Cobenfy and milvexian dataBMS reported second‑quarter revenue of $12.97 billion, topping analysts' estimate of $11.73 billion, and earnings per share of $2.04, well above the $1.60 consensus. The strong results prompted the…
- AtaiBeckley secured co-development and royalty offers before $2.8 B Lilly acquisitionAtaiBeckley, a psychedelic biotech, received co-development and royalty proposals prior to finalizing a $2.8 B acquisition by Eli Lilly. Details were disclosed in an SEC filing that outlined the s…